On 30 March 2026, it has been announced that Royalty Pharma plc (Nasdaq: RPRX), the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, entered into a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of USD 500 million in 2026 and 2027 to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases.
JNJ‑4804 is a novel co‑antibody therapy that blocks the complementary interleukin‑23 (IL‑23) and tumor necrosis factor (TNF) pathways, delivering synergistic effects on the pathogenesis of chronic immune‑mediated diseases.
Pestalozzi advised Johnson & Johnson as to matters of Swiss law of this transaction, alongside Ropes & Gray LLP.
See PR here: Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases | Royalty Pharma